September 23, 2026·6 min read·kpv, side effects, safety, alpha-msh, anti-inflammatory peptide, peptide research, canada
KPV side effects — what the research reports
KPV side effects by evidence tier: no human safety data exists, what the mouse colitis and skin studies did and did not look for, mechanistic considerations, purity as a confound and Canadian status.
KPV side effects — what the research reports — Canada Peptides
KPV is the tripeptide Lys-Pro-Val, the C-terminal end of α-melanocyte-stimulating hormone (α-MSH), studied since 1989 for anti-inflammatory activity in rodent colitis and skin models and in cell culture. Searches for "KPV side effects" imply an adverse-event profile exists. It does not: there is no human trial, no human pharmacokinetic study and no human safety study of KPV by any route. This page sets out what the animal studies did and did not look for, the considerations that follow from the mechanism, and the confounds that apply to any reaction reported outside a trial. It is a research reference beside the KPV profile, not advice and not a safety assurance.
Controlled human data: none
The strongest statement the literature supports is a negative one. No clinical trial has enrolled a person to receive KPV. No pharmacokinetic study has measured it in human plasma. No safety study has recorded adverse events. A related α-MSH-derived peptide entered early clinical testing for a fungal indication in the 2000s; KPV itself never did. The evidence tier that answers most safety questions for most compounds — controlled human trials — is empty here, and every statement below comes from a lower one.
What the animal studies reported
The rodent literature is consistent and narrow. Mouse colitis studies from two independent groups (Dalmasso, Gastroenterology, 2008; Inflammatory Bowel Diseases, 2008) gave KPV orally, in drinking water at around 100 µmol/L, and reported less weight loss, lower histological scores and lower cytokine levels than untreated controls, with no toxicity described. The nanoparticle follow-ups (Gastroenterology, 2010; Molecular Therapy, 2017) delivered far smaller amounts by colon-targeted carriers and again reported no toxicity. The original rabbit fever study (FASEB Journal, 1989) and later rodent endotoxin work used intraperitoneal doses in the low milligram-per-kilogram range without reported harm. Skin and keratinocyte studies applied it topically or in culture.
Three limits apply. These were efficacy experiments in disease models, designed to measure inflammation, not toxicology studies designed to find harm. They used oral, intraperitoneal and topical routes, not subcutaneous injection. And the amounts were small — the nanoparticle work delivered roughly 12,000-fold less peptide than the drinking-water experiment — so they say nothing about higher exposures. "No toxicity reported" in this record means no toxicity was looked for at those amounts.
Mechanism-derived considerations
KPV's origin — three residues of a hormone circulating in every human — is often cited as reassurance, and it is reasonable as far as it goes. The tripeptide lacks the His-Phe-Arg-Trp core that binds melanocortin receptors, and its activity has been reported in cells with little functional MC1R; several authors propose a receptor-independent mechanism through PepT1 uptake and inhibition of NF-κB signalling. That absence of melanocortin activity is why the pigmentation, nausea, flushing and blood-pressure signals that attach to Melanotan II and PT-141 are not expected with KPV, which is the one safety inference the mechanism supports with some confidence.
Two considerations cut the other way. A compound that suppresses NF-κB signalling could in principle blunt a useful inflammatory response, for instance to infection; the animal work did not show increased infection, and the 2000 antimicrobial reports (Journal of Leukocyte Biology) point the opposite direction, but the question has not been studied directly. And PepT1 is shared with certain oral antibiotics and antiviral prodrugs, so an interaction at the transporter is plausible and untested. Injection-site reactions are possible with any subcutaneous peptide.
Reports outside the literature
Community and vendor sources describe injection-site redness or tenderness and, occasionally, transient fatigue with KPV or blends containing it. These are uncontrolled, unblinded self-reports with no denominator; they cannot establish incidence, causation or severity, and for a compound with no human pharmacology they cannot even be checked against an expected profile. Treat them as hypotheses, not findings.
Purity as a confound
With no human data on the molecule, any reaction to research-market KPV is at least as likely to trace to the vial as to the tripeptide: synthesis impurities, residual solvents, endotoxin load, or the free-acid versus amidated versus D-lysine forms that publications do not always distinguish. KPV itself is chemically robust — no cysteine, no aromatic residues, no site for oxidation — so degradation is a smaller concern than contamination. The KLOW blend adds a second confound: four peptides in one vial mean a reaction cannot be attributed to any one of them, and the copper in GHK-Cu makes bruising at the site look worse than it is. Third-party HPLC analysis and a lot-specific certificate of analysis are the only way to separate compound effects from product effects — see lab testing and COAs and the cold-chain and shelf-life guide.
Regulatory and sport status
KPV has no Health Canada market authorisation and no DIN, has not been reviewed for safety or efficacy, and is not a controlled substance; research-grade KPV is sold in Canada, as the standalone vial here, for research use only. In September 2023 the U.S. FDA placed KPV in category 2 of its section 503A bulk-substances evaluation, citing the lack of human safety data rather than any specific harm; it may not be compounded there. KPV is not named on the WADA Prohibited List, and as an unapproved substance it falls under S0 for tested athletes, who should verify against the current list. The KPV research overview and the KLOW research overview cover the mechanism and the blend rationale.
Frequently asked questions
Does KPV have a documented side-effect profile?
No. There is no human trial, pharmacokinetic study or safety study of KPV by any route. The only data is from rodent efficacy experiments that reported no toxicity at the small oral, intraperitoneal and topical amounts used, without looking for it systematically.
Why are Melanotan II's side effects not expected with KPV?
KPV lacks the α-MSH core that activates melanocortin receptors, and its activity appears to run through PepT1 uptake and NF-κB inhibition instead. The pigmentation, nausea and flushing of Melanotan II and PT-141 are receptor effects KPV is studied precisely for not having.
What does "no toxicity reported" in the mouse studies mean?
That disease-model experiments measuring inflammation did not note harm at the amounts used. They were not toxicology studies, did not use injection, and delivered small amounts. It is the absence of looking, not evidence of safety.
Is KPV on the WADA Prohibited List?
Not by name. As a substance with no approval anywhere, it falls under the S0 non-approved-substances category for tested athletes.
Is this medical advice?
No. This page reports what the animal literature and regulators say about KPV. It is not medical advice, not a safety assurance, and not a suggestion that anyone administer the compound to a person.
